IRX Therapeutics, Inc.
Industry: Biotechnology (See others in industry)
Address:
654 Madison Avenue Suite 1601
New York, NY, 10065
Phone: 212-582-1199
New York, NY, 10065
Phone: 212-582-1199
Filings
| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2017-08-29 | Amended | $33,230,669 | $19,993,435 | Equity Only | 06b | SEC link |
| 2017-01-12 | New | $13,237,234 | $13,237,234 | Equity Only | 06b | SEC link |
| 2016-11-09 | New | $6,400,000 | $6,400,000 | Debt Only | 06b | SEC link |
| 2016-05-13 | New | $2,000,000 | $2,000,000 | Debt Only | 06b | SEC link |
| 2015-08-17 | Amended | $40,585,742 | $9,017,999 | Equity Only | 06b | SEC link |
| 2015-01-15 | New | $31,567,743 | $31,567,743 | Equity Only | 06b | SEC link |
| 2014-03-14 | New | $15,094,601 | $15,094,601 | Debt Only | 06b | SEC link |
| 2012-05-30 | New | $1,500,000 | $1,500,000 | Debt Only | 06 | SEC link |
| 2010-06-11 | New | $8,047,991 | $8,047,991 | Debt Only | 06 | SEC link |
| 2010-01-11 | New | $2,211,772 | $2,211,772 | Equity Only | 06 | SEC link |
| 2007-09-06 | Paper Filing | Unknown | Unknown | Other | Not Available |
Directors and Executives (Current and Past)
| Name | Role |
|---|---|
| Charles R. Cherington | Director |
| David H. Deming | Director |
| George P. Denny Iii | Director |
| John W. Hadden | Director |
| John W. Hadden Ii | Director, Executive |
| John D. Halpern | Director |
| Jeffrey Hwang | Executive |
| Jeffrey Hwuang | Executive |
| Mark W. Leuchtenberger | Director, Executive |
| Frank J. Loverro | Director |
| Ferid Murad | Director |
| Curtis P. Robb | Executive |
| Zygmund Roth | Executive |
| Monil Shah | Executive |
| John T. Spitznagel | Director |
| Howard H. Stevenson | Director |
| Edmund Truell | Director |
| Lawrence M. Wolf | Director |